Monthly Prescribing Reference

Mavyret Indication Expanded to Include Treatment of Acute Hepatitis C Virus

Findings showed that in patients treated with glecaprevir/pibrentasvir, the overall SVR12 rate was 96%, with 0 patients experiencing virologic failure. The Food and ...
Benzinga.com

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)

Editor's Note: This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV. Glecaprevir, one of the two DAAs in Mavyret, was Discovered ...
Seeking Alpha

U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

"The physical, emotional, and economic burden of a curable condition like hepatitis C is far too great in the United States and around the world," said John Ward, M.D., director, Coalition for Global ...
Seeking Alpha

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for ...

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
MedPage Today

Mavyret Approved for Acute Hepatitis C; ALD Deaths Double; Entyvio in Pregnancy

The FDA expanded the approval of the direct-acting antiviral (DAA) glecaprevir/pibrentasvir (Mavyret), making it the first treatment for acute hepatitis C virus ...
Nasdaq

U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

NORTH CHICAGO, Ill., June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for ...